Advertisement

Topics

Helsinn Group and DARA BioSciences, Inc. Company Profile

05:40 EDT 21st September 2018 | BioPortfolio

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business model is focused on the licensing of pharmaceuticals, medical devices and nutritional supplement products in therapeutic niche areas. Helsinn is an important player in cancer supportive care. Helsinn Group in-licenses early-to-late stage new chemical entities, completes their development through the performance of pre-clinical /clinical studies and Chemistry, Manufacturing, and Control (CMC) development, and files and attains their market approvals worldwide. Helsinn’s products are out-licensed to its network of local marketing and commercial partners, selected for their deep in-market knowledge and know-how whom Helsinn assists and supports by providing a full range of product and scientific management services, including commercial, regulatory financial, legal, and medical marketing advice. The active pharmaceutical ingredients and the finished products are manufactured according to the highest quality, safety, and environmental standards at Helsinn’s GMP facilities in Switzerland and Ireland and supplied worldwide to its customers. Further information on Helsinn Group is available at www.helsinn.com.


News Articles [1350 Associated News Articles listed on BioPortfolio]

Press Release: Helsinn Group and MEI Pharma -2-

Press Release: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatmen...

Helsinn Group to buy worldwide rights of Valchlor/Ledaga from Actelion Pharmaceuticals

Helsinn, a Swiss pharmaceutical group entered into a definitive agreement to acquire worldwide rights to Valchlor/Ledaga (mechlorethamine/chlormethine), an alkylating agent for the topical treatment o...

Swiss pharma group invests millions to safeguard supply chain and regulatory compliance

Swiss pharmaceutical group, Helsinn, has revealed it will be investing €6 million at its drug product supply centre (Helsinn Birex Pharmaceuticals — HBP) in Dublin, Ireland, to safeguard its suppl...

Helsinn gets global Valchlor/Ledaga rights from Actelion

Johnson & Johnson division Actelion Pharmaceuticals Ltd. granted Helsinn Group global rights to market the topical skin cancer drug Valchlor/Ledaga (mechlorethamine). Financial terms were not disclose...

Mundipharma & Helsinn expand licensing and distribution agreement to include Vietnam

Mundipharma and Helsinn Group have extended their licensing and distribution agreement for the anti-emetic agent ALOXI to now include Vietnam.

Pawar Law Group: Solid Biosciences Inc. Reminder: Important May 29, 2018 Lead Plaintiff Deadline in Class Action - SLDB

NEW YORK, NY / ACCESSWIRE / April 20, 2018 / Pawar Law Group reminds shareholders who purchased shares of Solid Biosciences Inc. (NASDAQ: SLDB): (1) in Solid Biosciences' initial public offering on...

Helsinn: Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Center

Second Conquer Cancer Foundation/Anna Braglia Endowed Young Investigator Award (YIA) in Cancer Supportive Care, supported by Helsinn, awarded to Rajiv Agarwal, MD, Memorial Sloan Kettering Cancer Cen...

Press Release: Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myeloid Leukemia (AML) in adult patients unfit f

Helsinn Group and MEI Pharma Announce Upcoming Presentation at ASCO 2018 on the design of the Phase III PRIMULA study of Pracinostat in combination with azacitidine for the treatment of Acute Myel...

Drugs and Medications [57 Associated Drugs and Medications listed on BioPortfolio]

Naturally nova scotia hand sanitizer [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Anhydrous spf 30 [Owen Biosciences, Inc.]

Drug Facts

Natelle one [Azur Pharma, Inc.]

Natelle OneRx Prenatal Vitamin & Plant-Based DHA Now with 28 mg Iron

Natelle one [Azur Pharma, Inc.]

Natelle®OneRx Prenatal Vitamin & Plant-Based DHA

PubMed Articles [1781 Associated PubMed Articles listed on BioPortfolio]

Infusion of Daratumumab in Combination Therapies - Practical Information for The Outpatient Area.

Combination therapies such as Dara-Rd and Dara-Vd show significantly higher survival rates after 12 months than the respective therapies without Daratumumab. The initial infusion of Daratumumab is ass...

Final size of a multi-group SIR epidemic model: Irreducible and non-irreducible modes of transmission.

A model of an epidemic outbreak incorporating multiple subgroups of susceptible and infected individuals is investigated. The asymptotic behavior of the model is analyzed and it is proved that the inf...

Introduction.

Contents list.

Back cover.

Clinical Trials [3932 Associated Clinical Trials listed on BioPortfolio]

A Study of Subcutaneous Versus (vs.) Intravenous Administration of Daratumumab in Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to show that subcutaneous (SC) administration of daratumumab co-formulated with recombinant human hyaluronidase PH20 (Dara SC) is non-inferior to intravenous (...

A Study to Determine the Efficacy of the Combination of Daratumumab (DARA) Plus Durvalumab (DURVA) (D2) in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

This is a single-arm, multicenter, Phase 2 study to evaluate the efficacy and safety of the combination regimen of daratumumab plus durvalumab (D2). The study will consist of 2 parts; Part...

A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

The purpose of this study is to evaluate complete response plus (+) very good partial response (CR+VGPR) rate following 4 cycles of induction therapy of daratumumab in combination with cyc...

Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

This study is a Phase Ib open label, single arm, adaptive multicentre trial. Patients with newly diagnosed Multiple Myeloma (MM) will be treated with Cyclophosphamide-Bortezomib-Dexamethas...

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the tolerability and safety of subcutaneous (SC) delivery of co-formulated daratumumab and rHuPH20 preparation (DARA SC) in Japanese participants w...

Companies [1989 Associated Companies listed on BioPortfolio]

Helsinn Group and DARA BioSciences, Inc.

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and operating subsidiaries in Ireland and the United States. Helsinn’s business mo...

DARA BioSciences, Inc.

DARA BioSciences, Inc. is a Raleigh, North Carolina based development-stage biopharmaceutical company that acquires promising therapeutic small molecules and develops them through...

Helsinn Healthcare SA

Helsinn is a privately owned pharmaceutical group with headquarters in Lugano, Switzerland, and subsidiaries in USA and Ireland. Helsinn's unique business model is focused on the licensing of phar...

HELSINN HEALTHCARE S.A.

Helsinn's strategy is focused on three activities Integrated Licensing Helsinn uses an innovative approach to develop and market new pharmaceutical products:INTEGRATED LICENSINGHelsinn adds scient...

DyoDelta Biosciences Ltd

DyoDelta Biosciences Ltd., is a London based company specialising in deals in the Pharma / Biotech sector.We provide best-practice in corporate transactions through our management and associates. DyoD...

More Information about "Helsinn Group and DARA BioSciences, Inc." on BioPortfolio

We have published hundreds of Helsinn Group and DARA BioSciences, Inc. news stories on BioPortfolio along with dozens of Helsinn Group and DARA BioSciences, Inc. Clinical Trials and PubMed Articles about Helsinn Group and DARA BioSciences, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Helsinn Group and DARA BioSciences, Inc. Companies in our database. You can also find out about relevant Helsinn Group and DARA BioSciences, Inc. Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Alzheimer's Disease
Of all the types of Dementia, Alzheimer's disease is the most common, affecting around 465,000 people in the UK. Neurons in the brain die, becuase  'plaques' and 'tangles' (mis-folded proteins) form in the brain. People with Al...


Corporate Database Quicklinks



Searches Linking to this Company Record